| cholangiolitic hepatitis | Hepatitis with inflammatory changes around small bile ducts, producing mainly obstructive jaundice; may be due to viral infection or bacterial infection ascending biliary tree because of obstruction. (05 Mar 2000) |
|---|---|
| cholestatic hepatitis | Jaundice with bile stasis in inflamed intrahepatic bile ducts; usually due to toxic effects of a drug. (05 Mar 2000) |
| chronic active hepatitis | <pathology> This is a form of continuing liver inflammation that results in liver cell death. Causes include viral infection (hepatitis D, hepatitis B, hepatitis C), autoimmune disease, drug ingestion or metabolic causes. Chronic active hepatitis will lead to hepatic failure and death in a small percentage of these patients. (27 Sep 1997) |
| chronic hepatitis | Any of several types of hepatitis persisting for more than six months, often progressing to cirrhosis. Synonym: chronic active liver disease. (05 Mar 2000) |
| chronic interstitial hepatitis | An obsolete term for cirrhosis of the liver. (05 Mar 2000) |
| chronic persistent hepatitis | <pathology> A form of hepatitis usually caused by hepatitis C or B, that consists of mild persistent liver inflammation. Often a mild elevation of the liver enzymes will be seen on liver profile or SMAC 25 assay. Liver biopsy indicates persistent hepatitis. Incidence: 1 in 1,000. (02 Jan 1998) |
| chronic persisting hepatitis | A form of chronic hepatitis that is usually benign, not progressing to cirrhosis, and usually asymptomatic without physical findings but with continuing abnormalities of tests of liver status. Synonym: chronic persistent hepatitis. (05 Mar 2000) |
| mouse hepatitis | A form of hepatitis in mice due to synergism between the mouse hepatitis virus and Eperythrozoon coccoides. Synonym: murine hepatitis. (05 Mar 2000) |
| plasma cell hepatitis | <pathology> A type of chronic active hepatitis that results from circulating auto-antibodies and chronic inflammation of the liver. Symptoms are those of chronic active hepatitis. (27 Sep 1997) |
| MS-1 hepatitis | A virus disease with a short incubation period (usually 15 to 50 days), caused by hepatitis A virus, a member of the family Picornaviridae, often transmitted by faecal-oral route; may be inapparent, mild, severe, or occasionally fatal and occurs sporadically or in epidemics, commonly in school-age children and young adults; necrosis of periportal liver cells with lymphocytic and plasma cell infiltration is characteristic and jaundice is a common symptom. Synonym: epidemic hepatitis, hepatitis A, infectious hepatitis, MS-1 hepatitis, short incubation hepatitis, virus A hepatitis. (05 Mar 2000) |
| halothane hepatitis | Hepatocellular damage said to result from the administration of halothane anaesthesia. (05 Mar 2000) |
| hepatitis | <pathology> Inflammation of the liver. (18 Nov 1997) |
| hepatitis A | <virology> A form of viral hepatitis, known as infectious hepatitis, due to its ability to be spread through personal contact with oral secretions or stool. Virus will be shed in the stools of an infected individual 2-3 weeks prior to the onset of any symptoms. Hepatitis A may also be transmitted sexually. Symptoms are similar to those of influenza, but the skin and eyes may become yellow. Recent travel to a third world country is a risk factor. There is no specific treatment but infected individuals should avoid potentially hepatotoxic substances. The virus is a small (27nm diameter) single stranded RNA virus with some resemblance to enteroviruses such as polio. (27 Sep 1997) |
| hepatitis agents, gb | Proposed members of the family flaviviridae. Gbv-b causes hepatitis in tamarins and possibly humans, and is the putative aetiological agent of a non-(a-e) hepatitis, gb hepatitis. (12 Dec 1998) |
| hepatitis a immunization | When immediate protection against hepatitis a (infectious hepatitis) is needed, immunoglobulins are used. Protection is effective only if given within 2 weeks of exposure and lasts but 2-4 months. Immunoglobulins can be used to protect household contacts of someone with acute viral hepatitis and travelers to regions with poor sanitation and high hepatitis a rates, when the traveler has to depart sooner than the vaccines can take effect (about 2 weeks). Travelers can receive the immunoglobulin and vaccine simultaneously and be protected immediately and for longer term. When immediate protection is not needed, hepatitis a vaccines are considered for individuals in high-risk settings, including frequent world travelers, sexually active individuals with multiple partners, homosexual men, individuals using illicit drugs, employees of daycare centres, and certain healthcare workers, and sewage workers. Two hepatitis a vaccines called havrix and vaqta are commercially available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection. (12 Dec 1998) |